ClinicalTrials.Veeva

Menu

Mynx M5 One Hour Ambulation Study

C

Cardiovascular Associates of the Delaware Valley

Status and phase

Completed
Phase 4

Conditions

Angiography

Treatments

Device: Endovascular Diagnostic Procedures

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01100476
2010 - M5

Details and patient eligibility

About

The Mynx Vascular Closure Device (Mynx M5) is a sponge-like material used to close the hole in the artery after patients undergo a diagnostic endovascular procedures

Full description

Key Inclusion:

  1. Patients >18 yrs of age
  2. Patient underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath via the common femoral artery.
  3. Patient is able to ambulate (routinely walk 6 meters or 20 feet without assistance for any reason) as assessed by investigator.

Enrollment

200 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient is > 18 years of age
  • Patient underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
  • Patient has been informed and understands the nature of the study and provides written INformed COnsent approved by the appropriate Institutional Review Board (IRB) prior to enrollment
  • Patient is able to ambulate (routinely walk 6 meters or 20 feet without assistance for any reason) as assessed by the investigator

Exclusion criteria

Pre-Procedure Exclusion Criteria

  • Patient had a prior surgical procedure, PTA, stent placement, or vascular graft in the common femoral artery
  • Patient has a bleeding disorder such as thrombocytopenia
  • Patient has uncontrolled hypertension
  • Patient is morbidly obese (BMI >40 kg/m2
  • Patient is pregnant or lactating
  • Patient has a documented INR >1.5 or patients currently receiving glycoprotein IIb/IIIa platelet inhibitor
  • Patient has a known severe allergy to contrast medium
  • Patient has a known allergy to PEG
  • Patient is unable to ambulate at one hour secondary to a co-morbid condition
  • Patient is know to require an extended hospitalization or re-hospitalization (e.g.patient is undergoing coronary artery bypass graft (CABG) surgery) or patient is scheduled to have a CABG surgery <30 days following the procedure

Intra-Procedure Exclusion Criteria

  • Common femoral artery is <5mm in diameter
  • Patient with clinically significant peripheral vascular disease in the vicinity of the puncture
  • Puncture site is located above the most inferior border of the inferior epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks
  • Patient has a posterior puncture or multiple punctures in an attempt to gain access
  • Patient has an ipsilateral venous sheath
  • Patient has a pre-existing arterial bleed/extravasation identified on pre-procedure femoral arteriogram, hematoma, pseudoaneurysm or arteriovenous fistula present prior to sheath removal
  • Patient has intra-procedural bleeding around the access site prior to sheath removal

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems